ISDA

Entry Detail

PDB ID:

5HI3

Keywords:

IMMUNE SYSTEM/INHIBITOR

Title:

Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists

Biological Source:

Source Organism:

Homo sapiens, synthetic construct

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2016-01-11

Release Date:

2016-08-31

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.15 Å

R-Value Free:

0.23

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Interleukin-17A
Chain IDs:A, B
Chain Length:132
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q16552 Pfam ID:PF06083

Polymer Type:polypeptide(L)
Description:CAT-2000 FAB heavy chain
Chain IDs:C, E (auth: H)
Chain Length:237
Number of Molecules:2
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Description:CAT-2000 FAB light chain
Chain IDs:D, G (auth: L)
Chain Length:214
Number of Molecules:2
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Description:synthetic IL-17A peptide inhibitor
Chain IDs:F (auth: I)
Chain Length:16
Number of Molecules:1
Biological Source:synthetic construct

Ligand Molecules

63O

Primary Citation

Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists.

Liu, S, Dakin, L.A, Xing, L, Withka, J.M, Sahasrabudhe, P.V, Li, W, Banker, M.E, Balbo, P, Shanker, S, Chrunyk, B.A, Guo, Z, Chen, J.M, Young, J.A, Bai, G, Starr, J.T, Wright, S.W, Bussenius, J, Tan, S, Gopalsamy, A, Lefker, B.A, Vincent, F, Jones, L.H, Xu, H, Hoth, L.R, Geoghegan, K.F, Qiu, X, Bunnage, M.E, Thorarensen, A.Show

Sci Rep 6 30859 30859 (2016)

PMID: 27527709 DOI: 10.1038/srep30859

Abstact

Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progressed into clinical trials. Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL-17A antagonists.

Legend

Protein

Chemical

Disease

Primary Citation of related structures